Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Apr 26;139(1):269–280.e7. doi: 10.1016/j.jaci.2016.03.028

Figure 4. High doses of IgG2 antibodies reveal FcγRIV contribution to IgG2-PSA.

Figure 4

(A) PSA in indicated mice injected with various doses of IgG2a anti-TNP mAbs (n=2/group). (B-E) PSA in indicated mice (B&C: n=8/group; D&E: n≥3/group) injected with indicated doses of anti-TNP mAbs. Data are pooled from two independent experiments. Significant differences compared to the untreated WT group are indicated.